AQST - アクエスティブ・セラピュ―ティクス (Aquestive Therapeutics Inc.) アクエスティブ・セラピュ―ティクス

 AQSTのチャート


 AQSTの企業情報

symbol AQST
会社名 Aquestive Therapeutics Inc (アクエスティブ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Aquestive Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant Sympazan and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108 and AQST-305 for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs which includes Suboxone and APL-130277 for the treatment of opioid dependence and Parkinson’s disease.   アクエスティブ・セラピュ―ティクスは米国の特殊医薬品企業。主に満たされていない医療ニ―ズに焦点を当て、製品の特定や開発、商業化に従事する。同社の「PharmFilm」は既存の処方薬を直接血流に送達するプラットフォ―ム医薬製剤。医薬品フィルム、個別使用フィルム、患者・医師・介護用のフィルムなどを製造する。本社所在地はニュ―ジャ―ジ―州ウォ―レン。   
本社所在地 30 Technology Drive Warren NJ 07059 USA
代表者氏名
代表者役職名
電話番号 +1 908-941-1900
設立年月日 37987
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 195人
url www.aquestive.com
nasdaq_url https://www.nasdaq.com/symbol/aqst
adr_tso
EBITDA EBITDA(百万ドル) -20.56200
終値(lastsale) 15.775
時価総額(marketcap) 393203343.425
時価総額 時価総額(百万ドル) 369.13940
売上高 売上高(百万ドル) 76.67900
企業価値(EV) 企業価値(EV)(百万ドル) 404.93140
当期純利益 当期純利益(百万ドル) -35.23500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aquestive Therapeutics Inc revenues increased 35% to $37.3M. Net loss applicable to common stockholders increased from $8.6M to $32.4M. Revenues reflect United States segment increase of 46% to $23.2M Malaysia segment increase of 22% to $33K. Higher net loss reflects Selling General and administrative increase from $10.6M to $41.2M (expense) Research_Development increase of 18% to $12.9M (expense).

 AQSTのテクニカル分析


 AQSTのニュース

   Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/25 14:15:00 GlobeNewswire
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and…
   Aquestive Therapeutics gets pathway for Libervant FDA resubmission (NASDAQ:AQST)  2020/11/18 21:49:44 Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for r
   Aquestive Therapeutics Analysts Estimate Report : What to Look Out for Stock market Insights & financial analysis  2020/11/04 21:31:00 Stock Market Daily
Aquestive Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Aquestive Therapeutics (NASDAQ:AQST) Lowered to “Sell” at Zacks Investment Research  2020/10/23 09:08:49 Transcript Daily
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which […]
   Aquestive Therapeutics (NASDAQ:AQST) Cut to “Sell” at Zacks Investment Research  2020/10/22 08:03:06 Zolmax News
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday morning, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline […]
   Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/25 14:15:00 GlobeNewswire
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and…
   Aquestive Therapeutics gets pathway for Libervant FDA resubmission (NASDAQ:AQST)  2020/11/18 21:49:44 Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for r
   Aquestive Therapeutics Analysts Estimate Report : What to Look Out for Stock market Insights & financial analysis  2020/11/04 21:31:00 Stock Market Daily
Aquestive Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Aquestive Therapeutics (NASDAQ:AQST) Lowered to “Sell” at Zacks Investment Research  2020/10/23 09:08:49 Transcript Daily
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which […]
   Aquestive Therapeutics (NASDAQ:AQST) Cut to “Sell” at Zacks Investment Research  2020/10/22 08:03:06 Zolmax News
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday morning, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline […]
   Aquestive Therapeutics (NASDAQ:AQST) Lowered to “Sell” at Zacks Investment Research  2020/10/23 09:08:49 Transcript Daily
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which […]
   Aquestive Therapeutics (NASDAQ:AQST) Cut to “Sell” at Zacks Investment Research  2020/10/22 08:03:06 Zolmax News
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday morning, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline […]
   Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7%  2020/10/21 10:14:47 Zolmax News
Aquestive Therapeutics Inc (NASDAQ:AQST) shot up 7% during trading on Monday . The company traded as high as $5.54 and last traded at $5.38. 768,810 shares were traded during trading, a decline of 18% from the average session volume of 936,964 shares. The stock had previously closed at $5.03. A number of research firms have […]
   Zacks Investment Research Lowers Aquestive Therapeutics (NASDAQ:AQST) to Sell  2020/10/21 06:36:49 Dakota Financial News
Aquestive Therapeutics (NASDAQ:AQST) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on […]
   Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates  2020/09/30 20:51:03 Benzinga
September proved to be a mixed month as far as drug approvals are concerned, with Mallinckrodt PLC (NYSE: MNK ) and Aquestive Therapeutics Inc (NASDAQ: AQST ) facing rejections. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Among the more fortunate ones were GlaxoSmithKline plc (NYSE: GSK ), which got the nod for an expanded indication - hypereosinophilic syndrome. Bristol-Myers Squibb Co's (NYSE: BMY ) leukemia drug also received FDA's blessings, and after several hiccups, Eton Pharmaceuticals Inc's (NASDAQ: ETON ) out-licensed preservative-free allergic conjunctivitis ophthalmic solution managed to win FDA approval . In another notable approval of the month, Roche Holdings AG's (OTC: RHHBY ) Gavreto was vetted to treat adults with metastatic RET fusion-positive non-small cell lung cancer.

 関連キーワード  (医薬品 米国株 アクエスティブ・セラピュ―ティクス AQST Aquestive Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)